

## Accepted Manuscript

Preformulation studies of ceftriaxone for pediatric non-parenteral administration as an alternative to existing injectable formulations

Tina Kauss, Mathieu Marchivie, Thida Phoeung, Alexandra Gaubert, Amélie Désiré, Giovanni Tonelli, Chantal Boyer, Marie-Hélène Langlois, Anthony Cartwright, Melba Gomes, Nicholas White, Karen Gaudin



PII: S0928-0987(17)30204-X

DOI: doi: [10.1016/j.ejps.2017.04.010](https://doi.org/10.1016/j.ejps.2017.04.010)

Reference: PHASCI 4000

To appear in: *European Journal of Pharmaceutical Sciences*

Received date: 26 October 2016

Revised date: 7 April 2017

Accepted date: 17 April 2017

Please cite this article as: Tina Kauss, Mathieu Marchivie, Thida Phoeung, Alexandra Gaubert, Amélie Désiré, Giovanni Tonelli, Chantal Boyer, Marie-Hélène Langlois, Anthony Cartwright, Melba Gomes, Nicholas White, Karen Gaudin , Preformulation studies of ceftriaxone for pediatric non-parenteral administration as an alternative to existing injectable formulations. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Phasci(2017), doi: [10.1016/j.ejps.2017.04.010](https://doi.org/10.1016/j.ejps.2017.04.010)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Title**

**Preformulation studies of ceftriaxone for pediatric non-parenteral administration as an alternative to existing injectable formulations**

**Authors**

Tina Kauss<sup>a,\*</sup>, Mathieu Marchivie<sup>b</sup>, Thida Phoeung<sup>a</sup>, Alexandra Gaubert<sup>1</sup>, Amélie Désiré<sup>a</sup>, Giovanni Tonelli<sup>a</sup>, Chantal Boyer<sup>a</sup>, Marie-Hélène Langlois<sup>a, 1</sup>, Anthony Cartwright<sup>c</sup>, Melba Gomes<sup>d</sup>, Nicholas White<sup>e,f</sup>, Karen Gaudin<sup>a, 1</sup>

<sup>a</sup> Univ. Bordeaux, EA 4575 Analytical and Pharmaceutical Developments Applied to Neglected Diseases and Counterfeits, Bordeaux, France

<sup>b</sup> Univ. Bordeaux, ICMCB CNRS-UPR 9048, Pessac, France

<sup>c</sup> Global Regulatory Solutions, Harpenden, UK

<sup>d</sup> Consultant, World Health Organization, Geneva, Switzerland

<sup>e</sup> Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, UK

<sup>f</sup> Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

\*Corresponding author: tina.kauss@u-bordeaux.fr; 146 rue Leo Saignat, 33076 Bordeaux, France, ☎++33557571229.

**Abstract**

Ceftriaxone, a third generation cephalosporin, has a wide antibacterial spectrum that has good CNS penetration, which makes it potentially suitable for initial treatment of severe neonatal pediatric infections providing suitable formulation. We evaluated its physicochemical and technical characteristics to assess its potential for development as a non-parenteral dosage

---

<sup>1</sup> Present address : ARNA, ChemBioPharm team, INSERM U1212, CNRS 5320, Univ. Bordeaux, Bordeaux, France

Download English Version:

<https://daneshyari.com/en/article/5547645>

Download Persian Version:

<https://daneshyari.com/article/5547645>

[Daneshyari.com](https://daneshyari.com)